JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an <i>in-vitro</i> B cell differentiation model and in patients with rheumatoid arthritis.

Front Immunol · 2023 · PMC9908612 · PMID 36776828

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Notably, we further detected a highly significant dose- and time-dependent reduction of switched memory (SM) B cells, strongest with JAK1/2 inhibition (upadacitinib > ruxolitinib > baricitinib > tofacitinib > filgotinib).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.